Arbor Realty Trust, Inc. is a nationwide real estate investment trust (REIT) and direct lender that originates, invests in, and services commercial real estate loans through structured and agency businesses across multifamily, single-family rental, bridge and mezzanine products.

# Arbor Realty Trust, Inc.

## Overview
Arbor Realty Trust is a nationwide real estate investment trust (REIT) and direct lender that originates and services loans for commercial real estate. The company operates through two primary segments: a Structured Loan Origination and Investment Business and an Agency Loan Origination and Servicing Business.

## Business segments

### Structured Loan Origination and Investment Business
- Invests in a diversified portfolio of structured finance assets across multifamily, single-family rental (SFR), and other commercial real estate markets.
- Principal products: bridge loans, mezzanine loans, junior participating interests in first mortgages, and preferred equity.
- Also participates in real estate joint ventures, direct property acquisitions, real estate-related notes, and mortgage-related securities.
- Private Label platform allows securitization of loans or retention of the lowest-risk tranches (APL certificates) while selling other tranches to investors.

### Agency Loan Origination and Servicing Business
- Originates, sells, and services multifamily mortgage loans through GSEs (Fannie Mae, Freddie Mac) and HUD, Ginnie Mae, and FHA programs.
- Retains servicing rights and asset management for substantially all loans originated and sold under GSE/HUD programs.
- Approved lender programs: Fannie Mae DUS, Freddie Mac Optigo, Freddie Mac SBL, and HUD MAP/LEAN.
- Also originates and sells Private Label loans under program guidelines, typically retaining servicing rights and potentially pooling/securitizing those loans.

## Corporate structure and tax
- Organized to qualify as a REIT for U.S. federal income tax purposes.
- Assets related to the Agency Business are held in taxable REIT subsidiaries (TRSs).
- Most operations are conducted through the operating partnership, Arbor Realty Limited Partnership (ARLP).

## Geography and scale (portfolio snapshot)
- Total loan and investment portfolio value: approximately $11.63 billion (2025).
- Large floating-rate loan portfolio: roughly 90% floating, 10% fixed.
- Unconsolidated equity affiliate stakes: $58.0 million.

## Key metrics and portfolio details (as of 12/31/2025)
- Total employees: 653

### Structured Business portfolio (as of 12/31/2025)
- Portfolio size: 632 loans
- Unpaid principal balance (UPB): $12.113 billion
- Weighted average pay rate: 6.49%
- Weighted average remaining months to maturity: 14.7 months (including extension options; 19.9 months if extensions included)

By asset class:
- Bridge Loans: 524 loans; UPB $11.3717 billion; pay rate 6.39%; average remaining maturity ~12.9 months
  - Multifamily: 224 loans
  - Single-Family Rental: 298 loans
  - Office: 1 loan
  - Retail: 1 loan
- Mezzanine Loans: 65 loans; UPB $290.2 million; pay rate 7.84%; average remaining maturity ~52.3 months
  - Multifamily: 63 loans
  - Other: 2 loans
- Construction: 34 loans (9 multifamily construction); UPB $249.0 million; pay rate 9.13%; average remaining maturity ~24.6 months
- Preferred Equity: 34 investments (32 Multifamily, 2 Other); UPB $202.1 million; pay rate 6.87%; average remaining maturity ~46.0 months

### Agency Business portfolio and activity (2025)
- Originations: $5.07 billion
- Sales: $5.10 billion
- Commitment volume: $5.10 billion
- Sales margin (gains and fees as a % of loan sales volume): 138 basis points
- MSR (mortgage servicing rights) rate: 107 basis points

### Agency servicing portfolio (by product and geography)
Product details:
- Fannie Mae (DUS): UPB $24.086 billion; ~66% of servicing UPB
  - Average life: ~5.5 years
  - Servicing fee rate: ~44.7 basis points
  - Geographic concentration (state): New York ~13%
- Freddie Mac (Optigo): UPB $7.455 billion; ~21% of servicing UPB
  - Average life: ~5.9 years
  - Servicing fee rate: ~18.3 basis points
  - Geographic concentration: Texas ~10%
- Private Label: UPB $2.558 billion; ~7% of servicing UPB
  - Average life: ~4.5 years
  - Servicing fee rate: ~18.7 basis points
  - Geographic concentration: North Carolina ~8%
- FHA: UPB $1.549 billion; ~4% of servicing UPB
  - Average life: ~19.1 years
  - Servicing fee rate: ~13.9 basis points
  - Geographic concentration: California ~7%
- Bridge loans serviced (sold to investors): UPB $0.278 billion; ~1% of servicing UPB
  - Average life: ~2.2 years
  - Servicing fee rate: ~10.4 basis points
  - Geographic concentration: Florida ~7%
- SFR - Fixed Rate: UPB $0.277 billion; ~1% of servicing UPB
  - Average life: ~4.0 years
  - Servicing fee rate: ~20.0 basis points
  - Geographic concentration: Georgia ~5%

Servicing portfolio total:
- UPB: $36.2037 billion (100% of servicing UPB)
- Weighted average life of loans: ~6.1 years
- Weighted average servicing fee rate: ~35.6 basis points

Geographic concentration (servicing portfolio):
- New York ~13%
- Texas ~10%
- North Carolina ~8%
- California ~7%
- Florida ~7%
- Georgia ~5%
- New Jersey ~5%
- Illinois ~4%
- Other ~41%

## Portfolio mix notes
- Structured Portfolio: ~90% floating-rate, ~10% fixed-rate
- Unconsolidated equity investments: $58.0 million

## Credit and funding posture
- Structured Business financing sources include CLOs, credit facilities, securitizations, and equity/debt offerings.
- Agency Business originations are financed via warehouse facilities and letters of credit with Fannie Mae, with risk-sharing and collateral requirements.
- The company uses hedging to manage interest rate risk in its floating-rate assets; hedges introduce counterparty and basis risk considerations.

## Business model and strategy
- The firm focuses on providing real estate financing across multiple product types, emphasizing rapid execution, credit quality, and borrower relationships.
- Agency Business operations are supported by established relationships with Fannie Mae, Freddie Mac, and HUD and provide a range of loan products with an integrated servicing framework.
- As a REIT, the company distributes a portion of taxable income to stockholders in accordance with REIT qualification requirements; TRSs handle non-exempt income activities related to the Agency Business.

AXIS Capital Holdings Limited is a global specialty insurer and reinsurer operating through two primary platforms (AXIS Insurance and AXIS Re) providing diversified insurance and reinsurance products across multiple jurisdictions.

# AXIS Capital Holdings Limited

## Overview
- Global specialty underwriter providing insurance and reinsurance solutions.
- Two main underwriting platforms: AXIS Insurance (primary underwriting) and AXIS Re (reinsurance).
- Operations in Bermuda, the United States, Europe, Singapore, and Canada.
- At December 31, 2025: common shareholders’ equity of $5.8 billion, total capital of $7.7 billion, and total assets of $34.5 billion.

## Business model and segments
- Two reportable segments: Insurance and Reinsurance.
- Assets are not allocated by segment except for goodwill and intangible assets.

## Insurance — lines of business and distribution
- Lines of business:
  - Professional Lines: directors’ and officers’ liability, errors and omissions, employment practices, fiduciary, crime, professional indemnity, medical malpractice, environmental liability, and related products.
  - Property: physical loss/damage, business interruption, machinery breakdown; includes catastrophe-exposed risks.
  - Liability: primary and low-to-mid level excess/umbrella; life sciences excess; UK products liability.
  - Cyber.
  - Marine and Aviation: marine (offshore energy, ocean marine, liability, hull); aviation (hull and liability).
  - Accident and Health.
  - Credit and Political Risk: credit insurance, political risk, surety, including some mortgage-related coverages.
- Distribution: primarily through wholesale and retail brokers worldwide; select products via managing general agents (MGAs) and managing general underwriters (MGUs). U.S. operations include admitted and non-admitted (surplus lines) capabilities.

## Reinsurance — lines of business and distribution
- Lines of business: liability, professional lines, motor, accident and health, credit and surety, agriculture, marine and aviation.
- Run-off lines (exited): catastrophe (as of June 2022), property (as of June 2022), engineering (exited in 2020).
- Distribution: mainly through reinsurance brokers globally; also operates via Lloyd’s Europe and related Lloyd’s platforms.

## Financial highlights (2025)
- Gross premiums written (GPW) by segment (amounts in thousands of U.S. dollars):
  - Insurance: $7,179,206
  - Reinsurance: $2,465,308
  - Total GPW: $9,644,514
  - Note: GPW figures are presented in thousands of U.S. dollars and are disclosed for the last three years (2025, 2024, 2023).
- Major broker contributions to GPW (2025; amounts in thousands):
  - Marsh & McLennan Companies Inc.: $627,507 (25%)
  - Aon plc: $583,418 (24%)
  - Arthur J. Gallagher & Co.: $570,384 (23%)
  - Other brokers: $461,483 (19%)
  - Direct: $134,556 (5%)
  - Managing general agencies and underwriters: $87,960 (4%)
- Corporate scale (as of December 31, 2025):
  - Common shareholders’ equity: $5.8 billion
  - Total capital: $7.7 billion
  - Total assets: $34.5 billion
- Employees: 1,966 as of December 31, 2025 (approximately a 5% increase in 2025). Voluntary turnover was 9.6% in 2025, versus 11.9% in 2024.

## Markets, customers, and distribution strategy
- Primary client and distribution relationships through global insurance and reinsurance brokers.
- Emphasis on broker relationships, product diversification, and balancing capacity across markets to manage underwriting cycles.
- No single insured accounted for more than 10% of gross premiums written in either segment.

## Geography and regulatory footprint
- Headquartered in Bermuda with operations in the U.S., Canada, Europe (including Dublin, London, Zurich, Brussels), and Singapore.
- U.S. entities regulated by state insurance departments.
- Uses Lloyd’s-related platforms for certain U.K. and Lloyd’s-based underwriting.
- Bermuda operations are subject to the Bermuda regulatory framework, including group solvency and local capital filings.
- European entities operate under Solvency II with related cross-border authorizations (e.g., AXIS Specialty Europe SE and AXIS Re SE).

## Risk, capital, and governance
- Focus on risk management, capital management, and diversification strategies, including internal risk capital modeling, risk appetite limits, and reinsurance/retrocession strategies to manage volatility.
- Governance and oversight include board risk and finance committees, an enterprise risk management (ERM) framework, and an internal model.
- Ongoing regulatory considerations include Solvency II adjustments and BEPS Pillar Two implications.

## Summary
AXIS Capital is a global specialty insurer and reinsurer operating through two primary platforms, with diversified lines of business and a multi-jurisdictional presence. In 2025 the company reported total gross premiums written of $9.644 billion, total capital of about $7.7 billion, total assets of about $34.5 billion, and 1,966 employees. Broker relationships are a core distribution channel, with several major brokers accounting for sizable portions of GPW.

Align Technology is a global medical device company that designs, manufactures, and markets the Invisalign clear aligner system, iTero intraoral scanners, and related digital dentistry software/services (Align Digital Platform and exocad).

# Align Technology, Inc.

## Overview
Align Technology, Inc. is a global medical device company that designs, manufactures, and markets:
- Invisalign clear aligners for treating malocclusions
- Vivera retainers for retention
- iTero intraoral scanners and related software and services for dentistry
- exocad CAD/CAM software for dental laboratories and practitioners

The company operates the Align Digital Platform, an end-to-end suite of software, systems, and services that connects patients, doctors, labs, and consumers across digital treatment workflows.

## Core products and platforms
- Invisalign System: Doctor-prescribed clear aligners created from a computer-simulated ClinCheck treatment plan. The workflow includes transmission of diagnostic data, digital treatment planning, manufacture of custom aligners (using 3D-printed molds), and sequential wear of aligners.
- iTero intraoral scanners: Handheld scanners for digital impressions with integrated software for orthodontic and restorative workflows. Newer generations include iTero Lumina and Lumina Pro (with NIRI) for enhanced imaging and restorative capabilities.
- exocad CAD/CAM software: Digital restoration workflows for labs and dental practices; licensed and sold separately.
- Align Digital Platform: Integrates the stages Connect, Scan, Diagnose, Plan, Treat, Monitor, and Retain. Platform tools include Invisalign Outcome Simulator Pro, iTero TimeLapse, iTero Design Suite, and Align Oral Health Suite.
- 2025 technology updates: Restorative capabilities for iTero Lumina, AI-driven features such as X-ray Insights, and updates to multiple iTero software workflows.

## Segments and revenue mix
- Operating segments:
  - Clear Aligner
  - Imaging Systems and CAD/CAM Services (Systems and Services)
- 2025 revenue mix: Clear Aligner net revenues ≈ 80% of worldwide net revenues; Systems and Services net revenues ≈ 20%.

## Scale and reach
- Patients treated: Over 22 million people worldwide have been treated with the Invisalign System.
- Doctors: Approximately 130,015 active Invisalign-trained doctors (as of December 31, 2025). Active defined as doctors who submitted at least one Invisalign case in the prior 12 months.
- Employees: Approximately 20,290 employees (as of December 31, 2025), a decline from 2024 and 2023 levels.
- Global footprint:
  - Sold directly or through authorized distributors in more than 100 countries (as of end of 2025).
  - Fabrication and treatment planning locations: 11 worldwide.
  - Manufacturing facilities (regional): Americas (Mexico), APAC (China), and EMEA (Poland).
  - iTero scanner manufacturing and assembly: Wand fabrication in Ziyang, China and Petah Tikva, Israel; final scanner assembly in Blonie, Poland and Juarez, Mexico; service and repair in Juarez, Mexico.
- Headquarters and regional hubs:
  - Corporate HQ: 410 North Scottsdale Road, Tempe, Arizona 85288
  - Americas regional HQ: Raleigh, North Carolina
  - EMEA regional HQ: Rotkreuz, Switzerland
  - APAC regional HQ: Singapore

## Market opportunity and adoption
- Global malocclusion market: Approximately 600 million people could benefit from straightening their teeth.
- Annual Invisalign case starts: About 22 million globally; Align estimates its share of this market at roughly 10% globally.

## Manufacturing and resilience
- Regions and facilities are organized to provide proximity to customers and operational redundancy.
- Certified to ISO 13485:2016.
- Multiple manufacturing and digital treatment planning locations support scale and continuity.

## Customer channels and delivery
- Primary customers: Orthodontists, general dentists (GPs), prosthodontists, periodontists, oral surgeons, and dental laboratories.
- Sales model: Direct sales force supplemented by distributors and sales agents; also sells to dental support organizations (DSOs) and dental labs.
- Consumer channels: Invisalign accessory products are sold through online and retail outlets, including accessories and whitening systems.
- Training and education: Invisalign training is required for doctors, supported by ongoing clinical support and education programs.

## Intellectual property and regulatory footprint
- Intellectual property: Broad patent portfolio and proprietary software/algorithms, including ClinCheck, iTero software, and exocad integration.
- Regulatory framework: U.S. FDA premarket clearance/510(k) pathway; EU Medical Device Regulation compliance; ISO 13485:2016 certification; privacy, data protection, and cybersecurity compliance across multiple jurisdictions.

## Strategic elements (2024–2025)
- Cubicure acquisition (completed January 2024): Provides direct fabrication and 3D printing capabilities to scale direct fabrication, reduce resin usage, and support mass production of custom devices.
- Product and workflow expansion: Continued push into restorative and digital workflows, AI-enabled insights, and expanded ortho-restorative capabilities (e.g., iTero Lumina Pro, Align X-ray Insights, Outcome Simulator Pro enhancements).

## Summary
Align Technology designs and sells the Invisalign System and iTero intraoral scanners, supported by the Align Digital Platform and exocad CAD/CAM software. The company operates two main business segments (Clear Aligner and Systems & Services), maintains a large international footprint, serves thousands of doctors, employs tens of thousands of people, and had a revenue mix in 2025 weighted toward clear aligners at about 80%.

ANI Pharmaceuticals is a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics across Rare Disease, Generics, and Brands to serve patients and improve lives.

# ANI Pharmaceuticals

## Overview
ANI Pharmaceuticals is a diversified biopharmaceutical company.

## Mission
"Serving Patients, Improving Lives" by developing, manufacturing, and commercializing therapeutics.

## Business focus
Operates through three core areas:
- Rare Disease
- Generics
- Brands

## Recent development
On September 16, 2024, ANI Pharmaceuticals acquired Alimera Sciences, Inc. As part of the acquisition, the company added two products: ILUVIEN® and YUTIQ®.

## Disclosures
See Note 3, "Business Combination," in the notes to the consolidated financial statements for details of the acquisition and its impact.

Medici List

ARBOR REALTY TRUST INC

Filed: 2026-02-27

AXIS CAPITAL HOLDINGS LTD

Filed: 2026-02-27

ALIGN TECHNOLOGY INC

Filed: 2026-02-27

ANI PHARMACEUTICALS INC

Filed: 2026-02-27